Robert I. Tepper Sells 24,777 Shares of CytomX Therapeutics, Inc. (CTMX) Stock
CytomX Therapeutics, Inc. (NASDAQ:CTMX) major shareholder Robert I. Tepper sold 24,777 shares of the firm’s stock in a transaction that occurred on Wednesday, October 4th. The shares were sold at an average price of $24.34, for a total value of $603,072.18. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.
Shares of CytomX Therapeutics, Inc. (CTMX) opened at 22.06 on Friday. The company’s market capitalization is $813.29 million. The company’s 50 day moving average price is $17.15 and its 200-day moving average price is $15.67. CytomX Therapeutics, Inc. has a 52 week low of $9.85 and a 52 week high of $24.67.
CytomX Therapeutics (NASDAQ:CTMX) last released its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.69) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.30). CytomX Therapeutics had a negative net margin of 206.33% and a negative return on equity of 84.61%. The business had revenue of $8.75 million during the quarter, compared to analyst estimates of $4.95 million. Analysts anticipate that CytomX Therapeutics, Inc. will post ($1.47) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Robert I. Tepper Sells 24,777 Shares of CytomX Therapeutics, Inc. (CTMX) Stock” was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another website, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/10/06/robert-i-tepper-sells-24777-shares-of-cytomx-therapeutics-inc-ctmx-stock.html.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. California State Teachers Retirement System lifted its holdings in CytomX Therapeutics by 27.8% in the second quarter. California State Teachers Retirement System now owns 51,430 shares of the biotechnology company’s stock valued at $797,000 after acquiring an additional 11,200 shares during the last quarter. The Manufacturers Life Insurance Company lifted its holdings in CytomX Therapeutics by 36.9% in the second quarter. The Manufacturers Life Insurance Company now owns 23,529 shares of the biotechnology company’s stock valued at $365,000 after acquiring an additional 6,342 shares during the last quarter. Redmile Group LLC lifted its holdings in CytomX Therapeutics by 2.4% in the second quarter. Redmile Group LLC now owns 698,392 shares of the biotechnology company’s stock valued at $10,825,000 after acquiring an additional 16,500 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new position in CytomX Therapeutics in the second quarter valued at approximately $174,000. Finally, State Street Corp lifted its holdings in CytomX Therapeutics by 58.8% in the second quarter. State Street Corp now owns 446,315 shares of the biotechnology company’s stock valued at $6,914,000 after acquiring an additional 165,342 shares during the last quarter. Hedge funds and other institutional investors own 59.97% of the company’s stock.
Several equities research analysts have recently issued reports on the company. Wedbush assumed coverage on CytomX Therapeutics in a research note on Thursday, September 7th. They issued an “outperform” rating and a $26.00 price objective for the company. Cann reaffirmed a “hold” rating on shares of CytomX Therapeutics in a research note on Tuesday, August 8th. Oppenheimer Holdings, Inc. reaffirmed a “hold” rating on shares of CytomX Therapeutics in a research note on Wednesday. BidaskClub lowered CytomX Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, July 24th. Finally, Cowen and Company reaffirmed a “buy” rating on shares of CytomX Therapeutics in a research note on Wednesday, June 28th. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and six have assigned a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $32.67.
CytomX Therapeutics Company Profile
CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.
Receive News & Stock Ratings for CytomX Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics Inc. and related stocks with our FREE daily email newsletter.